Compare Incyte Corporation (INCY) vs Constellation Brands Inc. Common Stock (STZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Constellation Brands Inc. Common Stock — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.63B), while Constellation Brands Inc. Common Stock trades at $128.99 (market cap $21.56B). The key difference: Incyte Corporation and Constellation Brands Inc. Common Stock are close in size by market cap, and Constellation Brands Inc. Common Stock pays a 3.23% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | STZ | |
|---|---|---|
Market Cap | $22.63B | $21.56B |
Volume | 1,869,988 | 1,626,934 |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $166.68 |
52-Week Low | $86.17 | $112.77 |
Typical Hold Time | 33 Days | — |
Enterprise Value | $18.13B | $31.78B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $108.62, down 2.46% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 13.84, robust profitability margins, and a significant earnings beat in Q2 2026. Recent news highlights FDA approval for Atebrioz and a strategic push for post-JAKAFI growth targeting $4B in sales. Operating cash flow surged to $1.41B in 2025, supporting financial health.
The outlook is mixed: analyst consensus is bullish with a $133.14 price target, but near-term technical pressure and Q3 2026's expected EPS loss pose risks. Long-term growth depends on pipeline execution and diversification beyond JAKAFI, with competitive and regulatory challenges as key investor considerations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Constellation Brands Inc. Common Stock
Constellation Brands, Inc. is a US producer and marketer of beer, wine, and spirits, known for importing Mexican beer brands Corona and Modelo alongside a portfolio of wine and craft spirits labels.
Read more on STZ →
